Welcome to our dedicated page for BridgeBio Oncology Therapeutics news (Ticker: BBOT), a resource for investors and traders seeking the latest updates and insights on BridgeBio Oncology Therapeutics stock.
BridgeBio Oncology Therapeutics, Inc. develops clinical-stage oncology therapeutics focused on RAS-pathway malignancies and cancers driven by RAS and PI3Kα biology. Company news centers on small-molecule pipeline updates, including BBO-11818, a selective oral pan-KRAS inhibitor, and BBO-10203, a RAS:PI3Kα breaker designed to disrupt oncogenic signaling.
Recurring updates include preclinical and clinical data presentations, oncology conference disclosures, FDA regulatory designations, publication of research data, inducement equity grants, and governance changes. BBOT also reports operating and financial results tied to development-stage biotechnology activities.
BridgeBio Oncology Therapeutics (BBOT) reported new Phase 1 data for KRASG12C inhibitor BBO-8520 and outlined a sharpened development focus in KRAS-mutant cancers.
In 2L+ KRASG12C inhibitor-experienced NSCLC, BBO-8520 plus pembrolizumab achieved an objective response rate (ORR) of 75% at the 500 mg QD dose and 53% across all dose levels (N=17), with a generally tolerable, mainly GI-related safety profile and favorable liver safety. As monotherapy in 2L+ KRASG12C inhibitor-naïve NSCLC, BBO-8520 showed 63% ORR (26/41), 100% disease control (41/41), and no grade 3 liver enzyme elevations; 75% (21/28) of eligible patients remained on treatment beyond six months.
BBOT will prioritize BBO-8520 combinations in 2L+ inhibitor-experienced NSCLC and BBO-11818/BBO-10203 combinations in KRAS-mutant cancers. Cash and investments of $344.1 million as of June 30, 2026 are projected to fund operations into 2028, with multiple data readouts expected from late 2026 through mid-2027.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) will participate in three investor healthcare conferences in September 2026: the Cantor Global Healthcare Conference on September 9 at 9:45 a.m. ET, Citi's Biopharma Back to School Conference on September 10 at 3:00 p.m. ET, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15 at 1:50 p.m. ET.
Live webcasts and 90-day replays will be available via the BBOT investor events webpage.
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) granted inducement equity awards on August 10, 2026 under its 2025 Inducement Plan to two employees hired in July 2026. The employees received non-qualified stock options for an aggregate 65,350 shares of common stock at an exercise price of $9.28 per share, equal to the Nasdaq closing price on the grant’s effective date.
According to BBOT, the options vest 25% on the first anniversary of each employee’s start date and monthly thereafter over 36 months, subject to continued service. The awards were granted outside stockholder-approved equity plans, under a plan adopted in October 2025, and approved by BBOT’s independent compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) reported second quarter 2026 results and clinical progress for its RAS-pathway pipeline targeting KRAS and PI3Kα malignancies. As of June 30, 2026, BBOT held $344.1 million in cash, cash equivalents and marketable securities, which the company expects will fund operations into 2028.
During the quarter, BBOT advanced monotherapy and combination cohorts for all three lead programs. It continued enrolling the BBO-8520 plus pembrolizumab NSCLC cohort and initiated a BBO-8520 plus BBO-10203 combination in KRASG12C NSCLC. For BBO-11818, BBOT continued monotherapy dose escalation, began dosing in combination with cetuximab, and after quarter-end initiated a combination with BBO-10203. At AACR, BBOT presented preclinical data showing potent activity of BBO-11818 in KRASG12D/V models, strong combination effects with cetuximab or BBO-10203, and complete tumor regressions when combined with anti–PD-1 in models.
BBO-10203 combination cohorts in HR+ breast cancer, HER2+/HR− breast cancer and colorectal cancer remained open for enrollment, supported by preclinical data demonstrating strong in vivo combination effects with tucatinib or trastuzumab in HER2-amplified models. Second quarter 2026 research and development expenses rose to $49.2 million from $27.4 million a year earlier, while general and administrative expenses increased to $11.0 million from $2.7 million, reflecting standalone operations, a de-SPAC transaction and one-time severance. Net loss widened to $56.5 million compared to $28.4 million in the prior-year quarter. On the balance sheet, BBOT reported total assets of $376.7 million, total liabilities of $53.6 million and stockholders’ equity of $323.1 million as of June 30, 2026.
BBOT (Nasdaq: BBOT) reported first quarter 2026 results and key RAS-pathway oncology updates. Three Phase 1 programs showed encouraging preliminary safety and efficacy, including a 65% ORR and 68% 6‑month PFS for BBO-8520 in KRASG12C NSCLC and a 56% tumor reduction PR for BBO-11818 in PDAC.
For the quarter, BBOT reported a net loss of $42.1 million, with R&D expenses of $39.8 million and G&A expenses of $6.4 million. Cash, cash equivalents and marketable securities totaled $388.9 million, expected to fund operations into 2028. Multiple clinical readouts are anticipated in the second half of 2026.
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) granted inducement stock options under its 2025 Inducement Plan on May 10, 2026. One new employee received options for 32,675 shares at an exercise price of $7.66 per share, vesting over four years, under Nasdaq Rule 5635(c)(4).
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) presented preclinical data on BBO-11818 at AACR 2026 showing an orally bioavailable, non-covalent pan-KRAS inhibitor that targets mutant KRAS in both ON (GTP-bound) and OFF (GDP-bound) states. The poster reports potent MAPK/ERK suppression, anti-proliferative activity, monotherapy tumor regressions, and enhanced efficacy in combinations across KRASG12D and KRASG12V models. Combination partners included BBO-10203, cetuximab, and anti-PD-1; complete regressions and an adaptive immune response were reported in the CT26 syngeneic model. Updated Phase 1 clinical data are expected in the second half of 2026.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced leadership changes effective April 20, 2026: Pedro J. Beltran, PhD named CEO, Idan Elmelech named COO, and Neil Kumar, PhD appointed Executive Chairman. The transition accompanies Phase 1b expansions and combination studies across RAS and PI3Kα malignancies.
Former CEO Eli Wallace, PhD, will remain as Senior Adviser to support ongoing programs and continuity.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) presented preclinical data for BBO-10203 at AACR Annual Meeting 2026 showing the RAS:PI3Kα breaker physically and allosterically disrupts RAS–PI3Kα interaction, inhibiting PI3Kα–AKT signaling.
Key findings: tumor regressions at 30 mg/kg QD, no hyperglycemia observed at 100 mg/kg QD, activity independent of RAS/PI3Kα mutational status, and strong in vivo combination activity with tucatinib and trastuzumab. Updated clinical data expected H2 2026.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced the U.S. FDA has granted Fast Track designation to BBO-11818 for treating adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma on April 20, 2026.
BBO-11818 is a pan-KRAS inhibitor in a Phase 1 trial (KONQUER-101); preliminary January 2026 data showed a confirmed partial response in pancreatic cancer and dose-dependent tumor reductions. Updated Phase 1 data expected in the second half of 2026.